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RuII(η6-arene) complexes, especially with bioactive ligands, are considered as very promising compounds 
for anticancer drug design. We have shown recently that RuII(η6-p-cymene) complexes with 3-
hydroxyflavone ligands exhibit very high in vitro cytotoxic activities correlating with a strong inhibition 
of topoisomerase IIα. In order to expand the structure-activity relationships and to determine the impact 10 
of lipophilicity of the arene ligand and of the hydrolysis rate on anticancer activity, a series of novel 3-
hydroxyflavone derived RuII(η6-arene) complexes were synthesised. Furthermore, the impact of the 
heteroatom in the bioactive ligand backbone was studied by comparing the cytotoxic activity of RuII(η6-p-
cymene) complexes of 3-hydroxyquinolinone ligands with that of their 3-hydroxyflavone analogues. To 
better understand the behaviour of these RuII complexes in aqueous solution, the stability constants and 15 
pKa values for complexes and corresponding ligands were determined. Furthermore, the interaction with 
the DNA model 5’-GMP and with a series of amino acids was studied in order to elucidate potential 
biological target structures. 
Introduction 
Ruthenium complexes represent a promising class of metal-based 20 
chemotherapeutics. The octahedral geometry of ruthenium, its 
binding ability to plasma proteins and the number of possible 
oxidation states in biological environments, makes it well suitable 
for drug design.1 By now, several ruthenium complexes have 
shown interesting properties in vivo and a generally lower 25 
toxicity than for platinum drugs was observed.2 Two RuIII 
compounds, namely [ImH][trans-Ru(DMSO)(Im)Cl4] (NAMI-A, 
Im = imidazole) and [IndH][trans-Ru(Ind)2Cl4] (KP1019, Ind = 
indazole) (Chart 1) are currently undergoing clinical trials with 
very promising results.3-5 30 
 
Chart 1. Structures of Ru anticancer agents. 
In the course of ruthenium anticancer drug development 
programmes, organometallic and especially half-sandwich 
RuII(η6-arene) complexes have more and more demonstrated their 35 
potential.6-10 Their hydrophobic arene ligand is thought to 
facilitate the diffusion through the lipophilic cell membrane.11 
The three remaining Ru coordination sites can be filled with 
various mono-, bi- or tridentate ligands, which offers a number of 
possibilities to modulate biological and pharmacological 40 
properties by proper ligand selection.12 Important examples for 
this substance type are RuII(arene) complexes of bidentate 
ethylenediamine, such as RM175 (Chart 1), and the RAPTA-type 
compounds containing the monodentate 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane (pta) ligand. RM175 binds to 45 
DNA either covalently via the N7 of guanine or non-covalently 
by intercalation of the arene, leading to cell death by modulation 
of the p53-p21-bax pathway.2,13 As opposed to this, the RAPTA 
compounds have very different chemical and biological 
properties. RAPTA-T (Chart 1) is selectively activated in the 50 
hypoxic conditions of solid tumours and is capable of inhibiting 
metastasis both in vitro and in vivo.4,14-16 Tethering ethacrynic 
acid to the arene ligand of RAPTA led to a compound capable of 
overcoming the glutathione transferase drug resistance 
mechanism of tumour cells and triggered several biological 55 
pathways involving either endonuclease G, caspases or c-Jun N-
terminal kinase.17 This is an example of linking a biological 
active molecule to a metal centre and modulating thereby its 
biological properties. Other related approaches involve 
RuII(arene) compounds with ligand systems that resemble the 60 
kinase inhibitor staurosporine18 or complexes of paullones, which 
are cyclin-dependent kinase (CDK) and glycogen synthase 
kinase-3 inhibitors.19 More recently, we have demonstrated that 
RuII(cym) (cym = η6-p-cymene) complexes of 3-hydroxyflavones 
are potent tumour cell growth inhibitors.20 65 
 3-Hydroxyflavones belong to the naturally occurring class of 
flavonoids which are polyphenols of plants, fruits and vegetables. 
They are well known for their beneficial effects on health due to 
their antioxidant and antiradical, antiinflammatory, antiviral and 
anticarcinogenic properties. These effects are caused primarily by 70 
 
the scavenging of free radicals by the flavonoid structure and 
interaction with a number of enzymes.21 Flavonoids are capable 
of forming stable chelate complexes with a broad range of 
ions, which have already shown biological activity in the 
treatment of diseases like AIDS, diabetes mellitus, some genetic 5 
diseases and also cancer.22 The RuII(cym
hydroxyflavones were found to exhibit not only 
anticancer activity in human cancer cell lines 
human topoisomerase IIα activity, which
cytotoxic potency.20 10 
In order to study the impact of the nature of the 
halogenido ligands on the stability and cytotoxic activity, 
of RuII(arene)X complexes with 3-hydroxyflavones has been 
synthesised. These properties are compared with those of 
structurally related 3-hydroxyquinolinone complexes featuring a 15 
nitrogen atom in the heterocyclic ligand. These studies are 
complemented with UV/vis and fluorescence spectroscopy 
experiments to gain information on the stability 
the hydrolysis products and ligand systems. 
Results and discussion 20 
Synthesis 
Within the course of a project to prepare 3
complexes, we have reported the synthesis of
cymene complexes with various substituted 3
and the influence of the substitution pattern 25 
substituent on the in vitro anticancer activity 
order to extend the structure-activity relationships (SAR
series of RuII(arene) complexes with 3-hydroxyflavone
3-hydroxyquinolinones d and e was synthesised
of the ligands with sodium methoxide and 30 
with the respective bis[dihalido(η6-
([RuX2(arene)]2; η
6-arene = cym, toluene, biphen
I), yielding complexes 1-13 in good to very good yields 
(Scheme 1). The compounds were characterised 
analytical methods (see experimental part) and 35 
over one year though exposed to sunlight and air
Scheme 1. Synthesis of RuII(η6-arene) complexes
the hydrolysis products 1’-13’ in aqueous solution
Behaviour and stability in aqueous solution
In order to study the properties of the 3- hydroxyflavone40 
RuII(cym) complexes in aqueous solution, the proton dissociation 
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Information) and the complex formation process of the 
by 
metal 
) complexes of 3-
high in vitro 
but also inhibit 
 correlates to their 
arene and 
a series 
and pKa values of 
-hydroxy-4-pyrone 
 ruthenium(II)-
-hydroxyflavones 
and the nature of the 
was studied.20,23 In 
s), a 
s a–c and 
 by deprotonation 
subsequent reaction 
arene)ruthenium(II)] 
yl; X = Cl, Br, 
with standard 
were stable for 
.  
 1-13 and formation of 
. a from refs. 20,23. 
 
-derived 
b, the hydrolysis of 
, Supporting 
corresponding complex 2 were investigated and stability and 
dissociation constants were studied.
 
Proton dissociation process of ligand 
The proton dissociation constant (p
determined by UV-vis spectrophotometry in 20% (w/w) dimethyl 
sulfoxide (DMSO)/H2O because of the poor solubility of the 75 
ligand and its complex in pure water. Since flavonoids may suffer 
from photodegradation,24 spectra were measured at various pH 
values employing the batch technique instead of continuous 
titrations. This guarantees minimal UV exposure and helps
avoiding photolysis, especially at high pH80 
pH-dependent spectra of the ligand s
increasing pH values. The deprotonation (HL 
attributed to the hydroxyl functional group 
bathochromic shift of the λmax and a small increase in intensity. 
The isosbestic point is constant at 366 n85 
at higher pH most probably due to the photodegradation of the 
ligand. Therefore, the pKa value 
spectra of the ligand species (HL, L
on the basis of deconvoluted spect
λmax values of both the protonated and the deprotonated forms of 90 
ligand b are identical to those of the unsubstituted 3
hydroxyflavone a.25 However, its p
due to the electron withdrawing effect of the fluoro substituent. 
The pKa of the structurally relate
0.01), which was also determined under the same conditions, 95 
in the same range as that of b.26 
Fig. 1. UV-vis spectra of ligand b at various pH values (a) and calculated 
individual absorbance spectra of the HL and L80 
10-5 M; T = 25˚C; I = 0.20 M (KCl); 20% (w/w) DMSO/H
342 nm (λ342 nm = 10210 mol
−1 dm3
10755 mol−1
In addition, the proton dissociation process of 85 
was monitored by ﬂuorimetry (Fig
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411 nm. The appearance of the two emission bands indicates t
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dependence of the fluorescence emission spectra shows that the 
emission intensity is strongly sensitive to the pH, and 
deprotonation results in a significant decrease of the intensity. 
From the spectral changes in water a pKa value of 8.30 ± 0.09 
was obtained, which verifies the pKa determined in 20% (w/w) 5 
DMSO/H2O and which is again in the same range as the pKa of 
maltol in aqueous solution (8.44).25 
 
Solution equilibria of [RuII(cym)X3]
n+ and complex 2 
In order to understand the behaviour of the flavonoid complex in 10 
aqueous solution, the hydrolysis of [RuII(cym)X3]
n+ (n = –1 – 2; 
X = Cl–, H2O or DMSO) needed to be determined under the same 
conditions. This was studied in 20% (w/w) DMSO/H2O by UV-
vis spectrophotometric titrations (Figure S2). Based on the 
spectral changes, stability constants of the minor 15 
[Ru2(cym)2(OH)2Xm]
n+ (m = 1, 2) and the major 
[Ru2(cym)2(OH)3]
+ dinuclear hydrolysis products were 
determined as log [(Ru(cym))2H−2]
2+ = −9.85 ± 0.06 and logβ 
[Ru2(cym)2H−3]
+ = −15.11 ± 0.03, respectively (Supporting 
Information). As the titrations were performed in the presence of 20 
0.2 M KCl, these constants are regarded as conditional stability 
constants. Similar but not identical speciation was found in pure 
aqueous solution.27 The presence of DMSO can suppress the 
hydrolysis of [RuII(cym)X3]
n+ which is then shifted to higher pH 
values (Figure S2b).  25 
 The complex formation processes of the ruthenium(II)-cym 
complex 2 were studied under the same conditions as for 
[RuII(cym)X3]
n+ (Figure 2a) and is compared to the maltol-
ruthenium(II)-cym system (Figure 2b).11 The pH-dependent 
spectral changes of the ruthenium(II)-cym-containing systems 30 
(Figure 2c) compared to the free ligands reveal that the complex 
formation starts pH > ~4 in both cases. The complex formation 
results in a significant shift of the λmax values and this new band is 
different from the bands belonging to the protonated and 
deprotonated forms of the metal-free ligands. This band is 35 
especially well-separated in the case of 2 (Figure 2a) (i.e. λmax of 
complex: 436 nm, HL: 342 nm, L−: 402 nm). Analysis of changes 
in the overlapping ligand and charge transfer (CT) bands shows 
the exclusive formation of mononuclear species 
[RuII(cym)(L)X]n+ with a 1:1 metal-to-ligand ratio. By 40 
deconvolution of the UV-vis spectra (Figure S3), a stability 
constant logβ ([RuII(cym)(L)X]n+) = 7.13 ± 0.08 for 2 was 
determined, which is in about the same range as the maltolato 
complex (logβ = 7.04 ± 0.05).  
 At neutral and alkaline pH various parallel processes take 45 
place, namely the complex [RuII(cym)(L)X]n+ starts to hydrolyse 
forming the mixed hydroxido species [RuII(cym)(L)(OH)] and to 
dissociate giving the tris-hydroxido-bridged dinuclear species 
[Ru2(cym)2(OH)3]
+ and the metal-free ligand (Figure 2d). The 
dissociation of (O,O)-pyrone ligands such as maltol of mono-50 
ligand complexes is relatively slow.28 However, in case of 
flavonoid complexes, the photodegradation of the ligand is a 
possible side reaction at pH > ~10. Due to these reasons the 
deconvolution of the spectra becomes more difficult and stability 
data of the [RuII(cym)(L)(OH)] species could only be obtained 55 
with lower accuracy as logβ = 0.3 ± 0.1 for 2 and 0.1 ± 0.1 for 
maltol. 
 
Fig. 2. (a) UV-vis spectra of 2 and (b) for comparison of a maltolato 
RuII(cym) complex at various pH values. (c) Absorbance values at 402 60 
nm (●) and at 436 nm (○) for complex 2 and at 322 nm (■) and at 328 nm 
(□) for the maltolato RuII(cym) complex plotted against the pH value. (d) 
Concentration distribution curves of the complex 2 {ccomplex = 5 × 10
-5 M 
(8 × 10-5 M in the case of maltol); T = 25 °C; I = 0.20 M (KCl); 20% 
(w/w) DMSO/H2O; pH = 2.5–11.5}.  65 
 Based on the increased proton dissociation constants of ligand 
b and maltol (see above), higher stability constants of 
[RuII(cym)(L)X]n+ are expected in 20% (w/w) DMSO/H2O than 
in pure aqueous solution. However, a logβ = 9.05 was reported 
for the maltolato complex in water,29 which is actually by two 70 
orders of magnitude higher than the constant obtained in 20% 
(w/w) DMSO/H2O mixture. DMSO complexes of Ru
II are known 
and DMSO coordination can suppress the formation of 
 
[RuII(cym)(L)X]n+ complexes. The speciation and the stability of 
2 and the maltolato complex show very strong similarities due to 
similar metal binding sites of the ligands. The fluorescence 
spectra of ligand b (Figure S1a) and complex 2 in aqueous 
solution (Figure S1b) show similar features up to pH ~4. When 5 
further increasing the pH, a band with high intensity at 448 nm 
develops reaching a maximum at pH ~5 and decreasing upon 
increasing pH. The appearance of this strong new band is most 
probably related to the formation of [RuII(cym)(L)X]n+, while the 
formation of the mixed hydroxido species [RuII(cym)(L)(OH)] is 10 
accompanied by a considerable loss of intensity. Therefore, this 
latter species seems to be much less fluorescent than 
[RuII(cym)(L)X]n+, but somewhat more fluorescent than the 
metal-free ligand. As also found for the maltolato complex, 
partial hydrolysis and dissociation of 2 are probable at 15 
physiological pH.  
Reactivity towards biomolecules 
In aqueous solution, compounds 1-3,20 5, 7, 9 and 11 are aquated 
immediately to the charged aqua species 1’-3’, 5’, 7’, 9’ and 11’, 
which can further react with biomolecules. The solubility of 4, 6, 20 
8 and 10 in aqueous solution limited investigations, however, due 
to the structural similarity similar behavior is expectable. Several 
RuII(arene) complexes are known to bind to the DNA model 
compound 5’-GMP and therefore are also able to form adducts 
with DNA, which is a possible target for metal-based anticancer 25 
agents.1,2,11,30-33 Similarly, 5, 7, 9 and 11 show interactions with 
5’-GMP, as observed in 1H NMR spectroscopy studies. However, 
due to their low solubility and even lower solubility of their 5’-
GMP adducts, the binding mode and stability of the adducts are 
elusive.   30 
 The 3-hydroxyquinolinone-derived RuII(arene) complexes 12 
(Figure S4) and 13 show the same aquation behaviour, but 
already 5 min after addition of D2O the first signs of the 
hydrolysis side product [Ru2(η
6-arene)2(OH)3]
+ were observed in 
the 1H NMR spectrum, which increased within 24 h. This side 35 
product is thermodynamically stable and unreactive towards 
nucleophiles.7 Compounds 12 and 13 bind immediately to the N7 
atom of 5’-GMP as indicated by an upfield shift of the H8 signal 
of 5’-GMP from approximately δ = 8.1 to 7.6 ppm (Figure S5). 
 To gain more insight into possible interactions with proteins 40 
and pharmacokinetic pathways, the reactions of the representative 
hydrolysis products 1’, 12’ and 13’ with the amino acids L-
methionine, L-histidine, L-cysteine and glycine were investigated 
(Figures S6–S12). The reactivity was found to be similar to 
pyrone-derived RuII(cym) complexes. All compounds reacted 45 
immediately with Met and His by replacement of the aqua ligand 
with the respective amino acid, which is coordinated to the RuII 
centre via the sulphur atom or via the N1 or N3 atoms of the 
imidazole moiety, respectively.11 In the case of 1’, the ligand was 
cleaved off and precipitated completely within 24 h. The same 50 
behaviour was observed for the 3-hydroxyquinolinone-derived 
complexes. However, after 24 h especially for 12’ still signals of 
coordinated quinolinone ligands were visible. This may be due to 
a slightly higher stability of the 3-hydroxyquinolinone complexes 
towards reaction with amino acids. Addition of Cys led to 55 
immediate decomposition of 1’ and to a lower extent of 13’. For 
12’ a reaction with Cys was observed (Figure 3) but the 
compound also decomposed partly within 24 h. In the case of 
glycine, also differing behaviour between 3-hydroxyflavone and 
quinolinone complexes was observed. Glycine reacted 60 
immediately with 1’, whereas the reaction with 12’ and especially 
13’ was significantly slower. Two minutes after addition only 
traces of coordinated glycine (two doublets at approximately δ = 
3.1 ppm)11 were observed in 12’ and only after 18 h in 13’, 
indicating again higher stability of the 3-hydroxyquinolinone 65 
complexes concerning reactions with amino acids. However, the 
cytotoxicity of 3-hydroxyflavone and quinolinone RuII(cym) 
complexes was similar (see below), although the MTT assay to 
determine the IC50 values is carried out in amino acid-containing 
medium. This indicates that the reaction with amino acids does 70 
not seem to significantly alter their in vitro anticancer potency, 
most probably due to their higher lipophilicity which may result 
in enhanced cellular uptake. 
Fig. 3. Reaction mixtures of 1’ (a) and 12’ (b) with equimolar amounts of 
L-cysteine analysed by 1H NMR spectroscopy after 5 min show 75 
immediate decomposition of 1’ after addition of Cys, whereas minor 
effects on the quinolinone signals of 12’ were observed. 
In vitro anticancer activity 
The cytotoxic activity of the RuII(arene) complexes was 
determined in the human cancer cell lines CH1 (ovarian 80 
carcinoma), SW480 (colon carcinoma) and A549 (non-small cell 
lung carcinoma) by means of the colorimetric MTT assay 
(Table 1). Recently, we have shown that the type and especially 
the position of the substituent on the phenyl ring of the ligand 
have a crucial impact on their biological activity.20 Meta- and 85 
para-substitution led to more cytotoxic compounds, whereas 
ortho-substituted or unsubstituted ligand structures showed less 
in vitro potency (Table 1, compare compounds 2 and 3 with 1). 
These data correlate well with the inhibition of topoisomerase IIα 
activity. All synthesised complexes exhibit promising tumour-90 
inhibiting properties with IC50 values in the low µM range, which 
is very remarkable for RuII(arene) complexes. In order to 
 
determine the effect of the lipophilicity on the anticancer activity, 
complexes bearing different arene ligands were synthesised. The 
toluene derivatives 8 and 9 exhibit a similar activity to their 
RuII(cym) analogues 1 and 3, whereas the biphenyl complexes 10 
and 11 are slightly less cytotoxic. Therefore, the influence of the 5 
arene ligands seems to be of minor importance for this type of 
compounds. The same activity pattern was observed for pyrone 
and especially thiopyrone-derived RuII(arene) complexes,19 which 
is in contrast to for example ethylenediamine complexes. The 
latter compound class showed a strong dependence of 10 
cytotoxicity on the coordinated arene. The change from benzene 
to p-cymene to biphenyl resulted in a large increase of their 
growth inhibitory activity in relation to an increasing size and 
hydrophobicity.34 It may be that the change in lipophilicity by the 
modification of the arene ligand is too marginal to outperform the 15 
contribution of the flavonoid ligand on the lipophilicity. 
Furthermore, as already shown for analogous pyrone- and 
thiopyrone RuII(arene) derivatives and also for ethylenediamine 
complexes, different halides as leaving groups show only little or 
no impact on the antiproliferative activity (compare 1, 3, 4–7). 20 
This can be explained by the quick aquation of the Ru centre, 
leading to the same aqua products. 
 When changing from 3-hydroxyflavones to 3-
hydroxyquinolinones as ligands, no improvement of the in vitro 
anticancer activity was observed. The quinolinone complexes 12 25 
and 13 exhibit cytotoxic activities in the same range as 1. Also 
variation of the unsubstituted 3-hydroxyquinolinone 12 to the 1-
methylated form in 13 showed no impact on the cytotoxic 
activity, indicating that the backbone of the ligand rather than the 
functional group seems to be crucial for the biological activity of 30 
this type of RuII(arene) complexes.  
Table 1. In vitro anticancer activity of 1–13 in ovarian (CH1), colon 
(SW480) and non-small cell lung carcinoma (A549) cell lines.a 
     IC50 [µM] 
 
R Y X arene CH1 SW480 A549 
1 b H O Cl cym 2.1 ± 0.2 9.6 ± 1.5 20 ± 2 
2 b p-F O Cl cym 1.7 ± 0.4 7.9 ± 2.1 18 ± 1 
3 b p-Cl O Cl cym 0.9 ± 0.1 3.8 ± 0.5 9.5 ± 0.5 
4 H O Br cym 2.8 ± 0.4 12 ± 1 27 ± 3 
5 p-Cl O Br cym 0.9 ± 0.1 3.4 ± 0.4 7.9 ± 0.6 
6 H O I cym 1.6 ± 0.2 9.6 ± 1.5 16 ± 1 
7 p-Cl O I cym 1.2 ± 0.3 4.7 ± 0.9 8.9 ± 0.8 
8 H O Cl tol 3.2 ± 0.1 12 ± 3 19 ± 1 
9 p-Cl O Cl tol 0.9 ± 0.2 4.7 ± 0.6 7.8 ± 2.5 
10 H O Cl biphen 5.5 ± 1.2 9.2 ± 1.9 28.3 ± 5.0 
11 p-Cl O Cl biphen 6.3 ± 1.1 21.1 ± 4.0 59.1 ± 1.1 
12 H N-H Cl cym 4.0 ± 0.2 14 ± 1 17 ± 2 
13 H N-CH3 Cl cym 5.3 ± 0.2 12 ± 2 19 ± 1 
a IC50 = 50% inhibitory concentration, 96 h exposure. 
b taken from refs. 
20,23. tol = toluene, biphen = biphenyl.  35 
Conclusions 
RuII(arene) complexes bearing biologically active ligand systems 
exhibit very interesting features and promising properties for 
anticancer drug design.12 3-Hydroxyflavone-derived RuII(arene) 
complexes are potent cytotoxic agents with good correlation to 40 
their topoisomerase IIα inhibitory activity.26 We have extended 
the series of compounds by varying the arene and halido ligands 
to learn about their influence on the biological activity, as well as 
compared the 3-hydroxyflavone complexes to quinolinone 
analogues in terms of cytotoxicity and reactivity towards 45 
biomolecules. All compounds exhibit in vitro anticancer activity 
in the low µM range and showed interaction with the DNA model 
compound 5’-GMP. Substitution of the arene and halido ligands 
had only a minor effect on the cytotoxic activity. The 3-
hydroxyquinolinone analogues behave similarly to the flavones in 50 
aqueous solutions and in anticancer activity assays, but are more 
stable in presence of amino acids. Extensive solution phase 
studies by NMR, UV-vis and fluorescence spectroscopy revealed 
that the para-fluoro substituted 3-hydroxyflavone b [2-(4-
fluorophenyl)-3-hydroxy-4H-chromen-4-one] exhibits a proton 55 
dissociation constant (pKa) of 8.70 ± 0.01 in 20% (w/w) 
DMSO/H2O and of 8.30 ± 0.09 in aqueous solution. The complex 
formation processes of the corresponding ruthenium(II)-cym 
complex 2 starts at pH > ~4, forming mononuclear species 
[RuII(cym)(L)X]n+ with a stability constant of logβ = 7.13 ± 0.08. 60 
At pH ≥ 7, hydrolysis of [RuII(cym)(L)X]n+ leads to the mixed 
hydroxido species [RuII(cym)(L)(OH)] (logβ = 0.3 ± 0.1) and 
partial dissociation giving the tris-hydroxido-bridged dinuclear 
species [Ru2(cym)2(OH)3]
+ and the metal-free ligand. The 
stability constants of the hydroxyflavone-derived  ruthenium(II)-65 
cym compounds are therefore in the range of structurally-related 
maltolato complexes. 
 Considering stability data and in vitro anticancer activity, 3-
hydroxyflavones seem to be a well-suited ligand system for 
anticancer RuII(cym)(chlorido) complexes and those represent a 70 
promising compound class for further drug design.  
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Experimental part 80 
Materials and methods 
All solvents were dried and distilled prior to use. All chemicals 
were purchased from commercial suppliers and used without 
further purification. Bis[(6-p-cymene)dichloridoruthenium(II)], 
bis[dichlorido(η6-toluene)ruthenium(II)],35 bis[(η6-85 
biphenyl)dichloridoruthenium(II)], bis[dibromido(η6-p-
cymene)ruthenium(II)], bis[(η6-p-
cymene)diiodidoruthenium(II)],36 3-hydroxy-2-phenyl-4H-
chromen-4-one (a), 2-(4-fluorophenyl)-3-hydroxy-4H-chromen-
4-one (b), 2-(4-chlorophenyl)-3-hydroxy-4H-chromen-4-one (c), 90 
[chlorido{3-(oxo-κO)-2-phenyl-chromen-4(1H)-onato-κO}(η6-p-
cymene)ruthenium(II)] (1), [chlorido{3-(oxo-κO)-2-(4-
fluorophenyl)-chromen-4(1H)-onato-κO}(η6-p-
cymene)ruthenium(II)] (2), [chlorido{3-(oxo-κO)-2-(4-
chlorophenyl)-chromen-4(1H)-onato-κO}(η6-p-95 
cymene)ruthenium(II)] (3),23 3-hydroxy-2-phenyl-1H-quinolin-4-
one (d) and 3-hydroxy-1-methyl-2-phenyl-1H-quinolin-4-one 
(e)37,38 were synthesised according to literature procedures.  
 
 Melting points were determined with a Büchi Melting Point B-
540 apparatus. Elemental analyses were carried out with a Perkin 
Elmer 2400 CHN Elemental Analyser at the Microanalytical 
Laboratory of the University of Vienna. NMR spectra were 
recorded at 25 °C using a Bruker FT-NMR spectrometer 5 
Avance IIITM 500 MHz. 1H NMR spectra were measured in 
CDCl3 at 500.10 MHz and 
13C{1H} NMR spectra at 125.75 MHz. 
The 2D NMR spectra were recorded in a gradient-enhanced 
mode.  
 10 
Synthetic procedures 
General complexation procedure:  
A solution of [(η6-arene)RuX(µ-X)]2 (η
6-arene = p-cymene, 
toluene, biphenyl; X = Cl, Br, I) in methanol (20 mL) was added 
to a solution of the ligand and sodium methoxide in methanol 15 
(20 mL). The reaction mixture was stirred at room temperature 
and under argon atmosphere for 20 h (except for 8 and 10 which 
were stirred for 6 h and 11 and 12 which were stirred for 5 h). 
The solvent was evaporated in vacuum; the residue was dissolved 
in dichloromethane, filtered and concentrated. Pure complexes 20 
were obtained by recrystallisation from methanol or precipitation 
from methanol with diethyl ether. 
 
[Bromido{3-(oxo-κO)-2-phenyl-chromen-4(1H)-onato-κO}(η6-
p-cymene)ruthenium(II)] (4): The reaction was performed 25 
according to the general complexation procedure using a 
(159 mg, 0.67 mmol), NaOMe (40 mg, 0.73 mmol) and [Ru(η6-p-
cymene)Br2]2 (200 mg, 0.25 mmol) affording 4 as an orange 
powder (130 mg, 47%). Mp: 169–171 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3): δ = 1.44–1.45 (m, 6H, CH3,Cym), 2.44 (s, 30 
3H, CH3,Cym), 3.02–3.08 (m, 1H, CHCym), 5.40–5.41 (m, 2H, 
H3/H5Cym), 5.68 (dd, 
3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, 
H2/H6Cym), 7.33–7.36 (m, 1H, H7), 7.38–7.41 (m, 1H, H4’), 
7.46–7.50 (m, 2H, H3’/H5’), 7.56 (d, 3J(H,H) = 8 Hz, 1H, H8), 
7.59–7.63 (m, 1H, H6), 8.22 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 35 
1H, H5), 8.60 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 2H, H2’/H6’) 
ppm; 13C{1H} NMR (125.75 MHz, CDCl3): δ = 18.9 (CH3,Cym), 
22.7 (CH3,Cym), 31.3 (CHCym), 78.4 (C3/C5Cym), 81.0 (C2/C6Cym), 
95.5 (C4Cym), 99.3 (C1Cym), 117.9 (C8), 120.1 (C8a), 124.1 (C7), 
124.6 (C5), 127.3 (C2’/C6’), 128.2 (C3’/C5’), 129.3 (C4’), 40 
132.5 (C2), 132.6 (C6), 149.1 (C1’), 153.8 (C4a), 154.8 (C3), 
183.5 (C4) ppm; elemental analysis calcd for C25H23BrO3Ru: 
C 54.35, H 4.20%; found: C 54.36, H 4.25%.  
 
[Bromido{3-(oxo-κO)-2-(4-chlorophenyl)-chromen-4(1H)-45 
onato-κO}(η6-p-cymene)ruthenium(II)] (5): The reaction was 
performed according to the general complexation procedure using 
c (191 mg, 0.70 mmol), NaOMe (44 mg, 0.81 mmol) and [Ru(η6-
p-cymene)Br2]2 (220 mg, 0.28 mmol) affording 5 as a red powder 
(210 mg, 64%). Mp: 164–167 °C (decomp.); 1H NMR 50 
(500.10 MHz, CDCl3): δ = 1.43–1.45 (m, 6H, CH3,Cym), 2.43 (s, 
3H, CH3,Cym), 3.00–3.07 (m, 1H, CHCym), 5.41 (dd, 
4J(H,H) = 1 
Hz, 3J(H,H) = 8 Hz, 2H, H3/H5Cym), 5.68 (dd, 
3J(H,H) = 5 Hz, 
3J(H,H) = 5 Hz, 2H, H2/H6Cym), 7.33–7.36 (m, 1H, H7), 7.44 (d, 
3J(H,H) = 9 Hz, 2H, H3’/H5’), 7.54 (d, 3J(H,H) = 8 Hz, 1H, H8), 55 
7.60–7.64 (m, 1H, H6), 8.21 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 
1H, H5), 8.55 (d, 3J(H,H) = 9 Hz, 2H, H2’/H6’) ppm; 13C{1H} 
NMR (125.75 MHz, CDCl3): δ = 19.1 (CH3,Cym), 22.5 (CH3,Cym), 
31.3 (CHCym), 78.4 (C3/C5Cym), 81.0 (C2/C6Cym), 95.9 (C4Cym), 
99.3 (C1Cym), 117.8 (C8), 120.0 (C8a), 124.2 (C7), 124.7 (C5), 60 
128.4 (C2’/C6’), 128.5 (C3’/C5’), 131.0 (C4’), 132.8 (C6), 
134.9 (C2), 147.9 (C1’), 153.8 (C4a), 154.8 (C3), 183.7 (C4) 
ppm; elemental analysis calcd for C25H22ClBrO3Ru∙0.25H2O: 
C 50.77, H 3.83%; found: C 50.79, H 3.77%. 
 65 
[Iodido{3-(oxo-κO)-2-phenyl-chromen-4(1H)-onato-κO}(η6-p-
cymene)ruthenium(II)] (6): The reaction was performed 
according to the general complexation procedure using a 
(128 mg, 0.54 mmol), NaOMe (33 mg, 0.61 mmol) and [Ru(η6-p-
cymene)I2]2 (208 mg, 0.21 mmol) affording 6 as red crystals 70 
(177 mg, 70%). Mp: 131–134 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3): δ = 1.47–1.48 (m, 6H, CH3,Cym), 2.45 (s, 
3H, CH3,Cym), 3.05–3.12 (m, 1H, CHCym), 5.45 (dd, 
3J(H,H) = 
5 Hz, 3J(H,H) = 5 Hz, 2H, H3/H5Cym), 5.73 (dd, 
3J(H,H) = 5 Hz, 
3J(H,H) = 5 Hz, 2H, H2/H6Cym), 7.34–7.37 (m, 1H, H7), 7.39–75 
7.42 (m, 1H, H4’), 7.47–7.50 (m, 2H, H3’/H5’), 7.58 (d, 3J(H,H) 
= 8 Hz, 1H, H8), 7.61–7.64 (m, 1H, H6), 8.20 (dd, 4J(H,H) = 
1 Hz, 3J(H,H) = 8 Hz, 1H, H5), 8.61 (dd, 4J(H,H) = 1 Hz, 3J(H,H) 
= 8 Hz, 2H, H2’/H6’) ppm; 13C{1H} NMR (125.75 MHz, 
CDCl3): δ = 18.6 (CH3,Cym), 22.7 (CH3,Cym), 31.9 (CHCym), 80 
77.7 (C3/C5Cym), 80.8 (C2/C6Cym), 95.0 (C4Cym), 99.5 (C1Cym), 
117.9 (C8), 120.1 (C8a), 124.1 (C7), 124.6 (C5), 
127.2 (C2’/C6’), 128.2 (C3’/C5’), 129.3 (C4’), 132.5 (C2), 
132.6 (C6), 149.1 (C1’), 153.9 (C4a), 155.1 (C3), 183.7 (C4) 
ppm; elemental analysis calcd for C25H23IO3Ru∙0.25H2O: 85 
C 49.72, H 3.92%; found: C 49.61, H 3.68%. 
  
[Iodido{3-(oxo-κO)-2-(4-chlorophenyl)-chromen-4(1H)-onato-
κO}(η6-p-cymene)ruthenium(II)] (7): The reaction was 
performed according to the general complexation procedure using 90 
c (151 mg, 0.55 mmol), NaOMe (36 mg, 0.67 mmol) and [Ru(η6-
p-cymene)I2]2 (217 mg, 0.22 mmol) affording 7 as a deep red 
powder (190 mg, 68%). Mp: 93–95 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3): δ = 1.45–1.46 (m, 6H, CH3,Cym), 2.42 (s, 
3H, CH3,Cym), 3.03–3.09 (m, 1H, CHCym), 5.44 (dd, 
3J(H,H) = 95 
5 Hz, 3J(H,H) = 5 Hz, 2H, H3/H5Cym), 5.72 (dd, 
3J(H,H) = 5 Hz, 
3J(H,H) = 5 Hz, 2H, H2/H6Cym), 7.33–7.36 (m, 1H, H7), 7.43 (d, 
3J(H,H) = 9 Hz, 2H, H3’/H5’), 7.54 (d, 3J(H,H) = 8 Hz, 1H, H8), 
7.60–7.63 (m, 1H, H6), 8.18 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 
1H, H5), 8.54 (d, 3J(H,H) = 9 Hz, 2H, H2’/H6’) ppm; 13C{1H} 100 
NMR (125.75 MHz, CDCl3): δ = 19.1 (CH3,Cym), 22.6 (CH3,Cym), 
31.5 (CHCym), 78.0 (C3/C5Cym), 80.9 (C2/C6Cym), 95.6 (C4Cym), 
99.3 (C1Cym), 117.9 (C8), 120.0 (C8a), 124.3 (C7), 124.6 (C5), 
128.3 (C2’/C6’), 128.5 (C3’/C5’), 131.0 (C4’), 132.9 (C6), 
134.9 (C2), 148.0 (C1’), 153.9 (C4a), 155.0 (C3), 183.8 (C4) 105 
ppm; elemental analysis calcd for C25H22ClIO3Ru∙0.25H2O: 
C 47.03, H 3.55%; found: C 46.95, H 3.50%. 
 
[Chlorido{3-(oxo-κO)-2-phenyl-chromen-4(1H)-onato-κO}(η6-
toluene)ruthenium(II)] (8): The reaction was performed 110 
according to the general complexation procedure using a 
(180 mg, 0.76 mmol), NaOMe (45 mg, 0.84 mmol) and [Ru(η6-
toluene)Cl2]2 (200 mg, 0.38 mmol) affording 8 as an orange 
powder (148 mg, 42%). Mp: 218–220 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3): δ = 2.41 (s, 3H, CH3,Tol), 5.39 (dd, 115 
3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, H2/H6Tol), 5.61 (dd, 
3J(H,H) 
 
= 5 Hz, 3J(H,H) = 5 Hz, 1H, H1Tol), 5.88–5.90 (m, 2H, H3/H5Tol), 
7.34–7.36 (m, 1H, H7), 7.39–7.42 (m, 1H, H4’), 7.48–7.51 (m, 
2H, H3’/H5’), 7.57 (d, 3J(H,H) = 8 Hz, 1H, H8), 7.61–7.64 (m, 
1H, H6), 8.24 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 1H, H5), 
8.61 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 2H, H2’/H6’) ppm; 5 
13C{1H} NMR (125.75 MHz, CDCl3): δ = 19.1 (CH3,Tol), 
29.9 (CHTol), 75.1 (C1Tol), 76.7 (C2/C6Tol), 85.2 (C3/C5Tol), 
98.9 (C4Tol), 117.8 (C8), 119.9 (C8a), 124.2 (C7), 124.6 (C5), 
127.4 (C2’/C6’), 128.3 (C3’/C5’), 129.4 (C4’), 132.3 (C2), 
132.7 (C6), 149.4 (C1’), 153.9 (C4a), 154.6 (C3), 183.4 (C4) 10 
ppm; elemental analysis calcd for C22H17ClO3Ru∙0.5H2O: 
C 55.64, H 3.82%; found: C 55.87, H 3.72%. 
 
[Chlorido{3-(oxo-κO)-2-(4-chlorophenyl)-chromen-4(1H)-
onato-κO}(η6-toluene)ruthenium(II)] (9): The reaction was 15 
performed according to the general complexation procedure using 
c (206 mg, 0.76 mmol), NaOMe (45 mg, 0.84 mmol) and [Ru(η6-
p-cymene)Cl2]2 (200 mg, 0.38 mmol) affording 9 as red crystals 
(281 mg, 74%). Mp: 217–219 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3): δ = 2.40 (s, 3H, CH3,Tol), 5.39 (dd, 20 
3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, H2/H6Tol), 5.61 (dd, 
3J(H,H) 
= 5 Hz, 3J(H,H) = 5 Hz, 1H, H1Tol), 5.88–5.91 (m, 2H, H3/H5Tol), 
7.34–7.38 (m, 1H, H7), 7.50 (d, 3J(H,H) = 8 Hz, 2H, H3’/H5’), 
7.52–7.54 (m, 1H, H4’), 7.56 (d, 3J(H,H) = 8 Hz, 1H, H8), 7.62–
7.65 (m, 1H, H6), 8.24 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 1H, 25 
H5), 8.56 (d, 3J(H,H) = 8 Hz, 2H, H2’/H6’) ppm; 13C{1H} NMR 
(125.75 MHz, CDCl3): δ = 19.1 (CH3,Tol), 29.9 (CHTol), 
75.1 (C1Tol), 76.7 (C2/C6Tol), 85.2 (C3/C5Tol), 98.6 (C4Tol), 
117.9 (C8), 120.0 (C8a), 124.3 (C7), 124.7 (C5), 
128.6 (C2’/C6’/C3’/C5’), 130.8 (C2), 133.0 (C6), 135.1 (C4’), 30 
148.2 (C1’), 153.9 (C4a), 154.6 (C3), 183.6 (C4); elemental 
analysis calcd for C22H16Cl2O3Ru: C 52.81, H 3.22%; found: 
C 52.62, H 3.14%. 
 
[Chlorido{3-(oxo-κO)-2-phenyl-chromen-4(1H)-onato-κO}(η6-35 
biphenyl)ruthenium(II)] (10): The reaction was performed 
according to the general complexation procedure using a 
(170 mg, 0.71 mmol), NaOMe (43 mg, 0.80 mmol) and [Ru(η6-
biphenyl)Cl2]2 (200 mg, 0.31 mmol) affording 10 as a deep red 
powder (279 mg, 86%). Mp: 203–206 °C (decomp.); 1H NMR 40 
(500.10 MHz, CDCl3): δ = 5.91–5.93 (m, 1H, H1Biphen), 5.96–
5.97 (m, 2H, H2/H6Biphen), 6.01–6.04 (m, 2H, H3/H5Biphen), 7.32–
7.35 (m, 1H, H7), 7.39–7.44 (m, 3H, H3’/H5’, H10Biphen), 7.47–
7.51 (m, 3H, H4’, H9/H11Biphen), 7.55 (d, 
3J(H,H) = 8 Hz, 1H, 
H8), 7.60–7.63 (m, 1H, H6), 7.90 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 45 
8 Hz, 1H, H8/H12Biphen), 8.16 (dd, 
4J(H,H) = 1 Hz, 3J(H,H) = 
8 Hz, 1H, H5), 8.47 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 2H, 
H2’/H6’) ppm; 13C{1H} NMR (125.75 MHz, CDCl3): δ = 
78.4 (C2/C6Biphen), 78.8 (C1Biphen), 83.0 (C3/C5Biphen), 
96.9 (C4Biphen), 117.8 (C8), 120.0 (C8a), 124.2 (C7), 124.5 (C5), 50 
127.4 (C2’/C6’), 128.2 (C3’/C5’), 128.8 (C9/C11Biphen), 
129.1 (C8/C12Biphen), 129.4 (C4’), 129.6 (C10Biphen), 132.1 (C2), 
132.7 (C6), 135.2 (C7Biphen), 149.5 (C1’), 153.9 (C4a), 
154.4 (C3), 183.3 (C4) ppm; elemental analysis calcd for 
C27H19ClO3Ru: C 61.42, H 3.63%; found: C 61.16, H 3.62%. 55 
  
[Chlorido{3-(oxo-κO)-2-(4-chlorophenyl)-chromen-4(1H)-
onato-κO}(η6-biphenyl)ruthenium(II)] (11): The reaction was 
performed according to the general complexation procedure using 
c (193 mg, 0.71 mmol), NaOMe (43 mg, 0.80 mmol) and [Ru(η6-60 
p-cymene)Cl2]2 (200 mg, 0.32 mmol) affording 11 as deep red 
crystals (245 mg, 68%). Mp: 194–197 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3): δ = 5.91–5.93 (m, 1H, H1Biphen), 5.95–
5.97 (m, 2H, H2/H6Biphen), 6.02–6.05 (m, 2H, H3/H5Biphen), 7.33–
7.38 (m, 3H, H3’/H5’/H7), 7.49–7.55 (m, 4H, H6/H8/ 65 
H9/H11Biphen), 7.60–7.64 (m, 1H, H10Biphen), 7.88–7.90 (m, 1H, 
H8/H12Biphen), 8.16 (dd, 
4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 1H, 
H5), 8.41 (d, 3J(H,H) = 9 Hz, 2H, H2’/H6’) ppm; 13C{1H} NMR 
(125.75 MHz, CDCl3): δ = 78.3 (C2/C6Biphen), 78.5 (C1Biphen), 
83.0 (C3/C5Biphen), 97.1 (C4Biphen), 117.8 (C8), 120.0 (C8a), 70 
124.3 (C7), 124.6 (C5), 128.4 (C2’/C6’), 128.6 (C3’/C5’), 
128.9 (C9/C11Biphen), 129.1 (C8/C12Biphen), 129.7 (C10Biphen), 
130.6 (C2), 132.9 (C6), 135.1 (C4’, C7Biphen), 148.4 (C1’), 
153.9 (C4a), 154.4 (C3), 183.5 (C4); elemental analysis calcd for 
C27H18Cl2O3Ru∙H2O: C 55.87, H 3.47%; found: C 55.86, 75 
H 3.17%. 
 
[Chlorido{3-(oxo-κO)-2-phenyl-quinolon-4(1H)-onato-O}( 
η6-p-cymene)ruthenium(II)] (12): The reaction was performed 
according to the general complexation procedure using d 80 
(172 mg, 0.73 mmol), NaOMe (43 mg, 0.8 mmol) and [Ru(η6-p-
cymene)Cl2]2 (200 mg, 0.33 mmol) to afford 12 as a orange 
powder (195 mg, 59%). Mp: 177–180 °C (decomp.); 1H NMR 
(500.10 MHz, CD3OD): δ = 1.41 (m, 6H, CH3,Cym), 2.37 (s, 3H, 
CH3,Cym), 2.88–2.96 (m, 1H, CHCym), 5.57 (d, 
3J(H,H) = 5 Hz, 85 
2H, H3/H5Cym), 5.81 (d, 
3J(H,H) = 6 Hz, 2H, H2/H6Cym), 7.40–
7.44 (m, 1H, H7), 7.55–7.63 (m, 4H, H3’/H4’/H5’/H6), 7.76 (d, 
3J(H,H) = 8 Hz, 1H, H8), 8.07–8.09 (m, 2H, H2’/H6’), 8.30 (dd, 
4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 1H, H5) ppm; 13C{1H} NMR 
(125.75 MHz, CD3OD): δ = 17.2 (CH3,Cym), 21.3 (CH3,Cym), 90 
31.2 (CHCym), 77.3 (C3/C5Cym), 79.6 (C2/C6Cym), 95.9 (C4Cym), 
98.3 (C1Cym), 117.9 (C8), 120.0 (C8a), 122.4 (C5), 123.4 (C7), 
128.2 (C3’/C5’), 129.0 (C2’/C6’), 129.4 (C4’), 129.6 (C6), 
132.3 (C2), 135.3 (C4a), 136.3 (C1’), 152.6 (C3), 174.9 (C4) 
ppm; elemental analysis calcd for C25H24ClNO2Ru·0.8CH2Cl2: 95 
C 53.90, H 4.49%, N 2.44%; found: C 54.01, H 4.78%, N 2.27%. 
 
[Chlorido{3-(oxo-κO)-1-methyl-2-phenyl-quinolon-4(1H)-
onato-O}( η6-p-cymene)ruthenium(II)] (13): The reaction was 
performed according to the general complexation procedure using 100 
e (180 mg, 0.73 mmol), NaOMe (43 mg, 0.8 mmol and [Ru(η6-p-
cymene)Cl2]2 (200 mg, 0.33 mmol) to afford 13 as an orange 
powder (157 mg, 46%). Mp: 188–190 °C (decomp.); 1H NMR 
(500.10 MHz, CD3OD): δ = 1.31-1.33 (m, 6H, CH3,Cym), 2.27 (s, 
3H, CH3,Cym), 2.77–2.85 (m, 1H, CHCym), 3.74 (N-CH3), 5.45 (d, 105 
3J(H,H) = 5 Hz, 2H, H3/H5Cym), 5.67 (d, 
3J(H,H) = 6 Hz, 2H, 
H2/H6Cym), 7.50–7.53 (m, 3H, H3’/H5’/H7), 7.61–7.66 (m, 3H, 
H2’/H4’/H6’), 7.72–7.75 (m, 1H, H6), 7.87 (d, 3J(H,H) = 8 Hz, 
1H, H8), 8.44 (dd, 4J(H,H) = 1 Hz, 3J(H,H) = 8 Hz, 1H, H5) ppm; 
13C{1H} NMR (125.75 MHz, CD3OD): δ = 17.1 (CH3,Cym), 110 
21.3 (CH3,Cym), 31.2 (CHCym), 37.6 (N-CH3), 77.6 (C3/C5Cym), 
79.5 (C2/C6Cym), 96.4 (C4Cym), 97.9 (C1Cym), 116.8 (C8), 
120.9 (C8a), 123.3 (C5), 123.5 (C7), 128.5 (C3’/C5’), 
129.2 (C2’/C6’), 130.1 (C4’), 130.3 (C6), 132.3 (C2), 
136.3 (C1’), 141.8 (C4a), 152.9 (C3), 174.0 (C4) ppm; elemental 115 
analysis calcd for C25H24ClNO2Ru·CH2Cl2: C 53.52, H 4.66%, 
 
N 2.31%; found: C 53.48, H 4.52%, N 2.20%. 
 
UV-vis spectrophotometric and spectrofluorimetric 
measurements 
Maltol, KCl, KOH, HCl and dimethyl sulfoxide (DMSO) were 5 
purchased from Sigma-Aldrich. Stock solutions of maltol, b and 
2 were prepared in a 20% (w/w) DMSO/H2O mixture or in H2O. 
The stock solution of [RuII(cym)X3]
n+ was obtained by dissolving 
a known amount of [RuII(cym)Cl2]2 in water and the exact 
concentration (~5 × 10-3 M) was determined with pH-10 
potentiometric titrations in aqueous solution at 25.0 ± 0.1 ºC at an 
ionic strength of 0.20 M (KCl) employing literature data for 
[Ru2(cym)2(OH)2Xm]
n+ (m = 1, 2) complexes.29  
A Hewlett Packard 8452A diode array spectrophotometer was 
used to record the UV-vis spectra in the interval 200–800 nm. 15 
The path length was 1 cm. The measurements for determination 
of the protonation constants of the ligands and the overall 
stability constants of the metal complexes were carried out at 
25.0 ± 0.1 ºC in a 20% (w/w) DMSO/H2O mixture and at an ionic 
strength of 0.20 M. The titrations were performed with carbonate-20 
free KOH solutions of known concentration (0.20 M). The 
concentrations of the KOH and HCl solutions were determined 
by pH-potentiometric titrations. An Orion 710A pH-meter 
equipped with a Metrohm combined electrode (type 6.0234.100) 
and a Metrohm 665 Dosimat burette were used for the pH-25 
potentiometric measurements. The electrode system was 
calibrated to the pH = −log[H+] scale in DMSO/water solvent 
mixtures by means of blank titrations (strong acid vs. strong base; 
HCl vs. KOH), similarly to the method suggested by Irving et al. 
in pure aqueous solutions.25 The average water ionisation 30 
constant, pKw, was determined as 14.30 ± 0.02 at 25.0 ºC and I = 
0.20 M (KCl), which corresponds well to literature data.39 
Protonation and stability constants and the individual spectra of 
the species were calculated with the computer program 
PSEQUAD.40 MpLqHr is defined for the general equilibrium 35 
pM + qL + rH  ∏ MpLqHr as (MpLqHr) = [MpLqHr]/[M]
p[L]q[H]r 
where M denotes [RuII(cym)X3]
n+ and L the completely 
deprotonated ligand. 
The spectrophotometric titrations were performed on samples 
containing either ligand b, maltol or [RuII(cym)X3]
n+, 40 
[RuII(cym)X3]
n+ and maltol, or complex 2 in 20% (w/w) 
DMSO/H2O. The concentration of ligands was 5−8 × 10
–5 M and 
the metal-to-ligand ratios were 1:1 and 1:2 in the case of maltol 
over the pH range 2.0–11.5. Complex 2 was titrated at a 
concentration of 5 × 10–5 M and [RuII(cym)X3]
n+ at 1.8 × 10–4 M.  45 
The pH-dependent fluorescence measurements of b and 2 were 
carried out on a Hitachi-4500 spectrofluorimeter with the 
excitation at 342 nm in aqueous solution at 25.0 ± 0.1 ºC and an 
ionic strength of 0.20 M (KCl). The emission spectra were 
recorded in 1 cm quartz cell in the pH range 2.0–11.5 using 50 
10 nm/10 nm slit widths. The samples contained the compounds 
at 1.5 × 10–5 M concentration.  
Due to the photosensitivity of b and 2, the batch technique was 
used for recording the UV-vis and fluorimetric spectra instead of 
continuous titrations and the solutions were kept in the dark. 55 
 
Hydrolysis, interaction with 5’-GMP and amino acids 
Hydrolysis and stability in water were investigated by 1H NMR 
spectroscopy. Due to the lipophilic character of the 
organometallics, all experiments were performed in 10% (v/v) d6-60 
DMSO/D2O solutions. For the interaction with 5’-GMP, the 
complexes (ca. 0.1 mg/mL) were dissolved in 10% (v/v) d6-
DMSO/D2O, yielding the corresponding highly reactive aqua 
species. The aqua complexes were converted in situ by addition 
of 50 μL aliquots of 5’-GMP solution (10 mg/mL) into the 65 
respective 5’-GMP adduct and the reaction was monitored by 1H 
NMR spectroscopy. To investigate the reactivity towards amino 
acids, the aqua complexes (ca. 0.1 mg/mL) were treated with 
equimolar amounts of amino acids and 1H NMR spectra were 
recorded after 5 min and 24 h. 70 
 
Cytotoxicity in cancer cell lines  
Cell lines and culture conditions 
CH1 cells originate from an ascites sample of a patient with a 
papillary cystadenocarcinoma of the ovary and were a gift from 75 
Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, Institute 
of Cancer Research, Sutton, UK. SW480 (human 
adenocarcinoma of the colon) and A549 (human non-small cell 
lung cancer) cells were provided by Brigitte Marian (Institute of 
Cancer Research, Department of Medicine I, Medical University 80 
of Vienna, Austria). All cell culture reagents were obtained from 
Sigma-Aldrich Austria. Cells were grown in 75 cm² culture flasks 
(Iwaki) as adherent monolayer cultures in Minimum Essential 
Medium (MEM) supplemented with 10% heat inactivated fetal 
calf serum, 1 mM sodium pyruvate, 4 mM L-glutamine and 1% 85 
non-essential amino acids (100x). Cultures were maintained at 
37 °C in humidified atmosphere containing 95% air and 5% CO2. 
 
MTT assay  
Cytotoxicity was determined by the colorimetric MTT [3-(4,5-90 
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, 
Sigma] microculture assay. For this purpose, cells were harvested 
from culture flasks by trypsinisation and seeded in 100 μL/well 
aliquots into 96-well microculture plates (Iwaki). Cell densities of 
1.5 × 103 cells/well (CH1), 2.5 × 103 cells/well (SW480) and 4 × 95 
103 cells/well (A549) were chosen in order to ensure exponential 
growth of untreated controls throughout the experiment. Cells 
were allowed to settle and resume exponential growth in drug-
free complete culture medium for 24 h. Stock solutions of the test 
compounds in DMSO were diluted in complete culture medium 100 
so that the maximum DMSO content did not exceed 1%. These 
dilutions were added in 100 μL/well aliquots to the microcultures 
and cells were exposed to the test compounds for 96 h. At the end 
of exposure, all media were replaced by 100 μL/well RPMI1640 
culture medium (supplemented with 10% heat-inactivated fetal 105 
bovine serum) plus 20 μL/well MTT solution in phosphate-
buffered saline (5 mg/ml). After incubation for 4 h, the 
supernatants were removed, and the formazan crystals formed by 
viable cells were dissolved in 150 μL DMSO per well. Optical 
densities at 550 nm were measured with a microplate reader 110 
(Tecan Spectra Classic), using a reference wavelength of 690 nm 
to correct for unspecific absorption. The quantity of viable cells 
was expressed in terms of T/C values by comparison to untreated 
controls, and 50% inhibitory concentrations (IC50) were 
calculated from concentration-effect curves by interpolation. 115 
Evaluation is based on means from at least three independent 
 
experiments, each comprising at least three replicates per 
concentration level.  
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